Dainippon Sumitomo Pharma Co., Ltd. announced that the Company has obtained a manufacturing and marketing approval for “Avapro® tablet 50 mg / 100 mg” (generic name: irbesartan) as of April 16, 2008 from Ministry of Health, Labor and Welfare.
Avapro® is a long-acting ARB (angiotensin II receptor antagonist) with a long half-life in blood and a 24-hour-lasting blood pressure-lowering effect, having high anti-hypertensive effect in mild to severe hypertension.
The Company intends to launch Avapro® after it is listed in the national health insurance drug price standard.
The Company sells a variety of antihypertensive drugs including Amlodin®, a long-acting calcium antagonist, and anticipates further contribution to treatment of high blood pressure through the expansion of antihypertensive product line with the addition of Avapro®.
No comments:
Post a Comment